Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature

Lung Cancer, 05/17/2012

The reports suggest that dose–reduction plays a limited role in preventing recurrence. Many patients received corticosteroids during retreatment, but not the one with recurrence of interstitial lung disease. This may suggest that corticosteroids can prevent recurrence due to their antiinflammatory properties.

Print Article Summary Cat 2 CME Report